Financial Performance - The company achieved total revenue of 78,962.66 million yuan in the first three quarters of 2014, representing a year-on-year growth of 21.95% [2] - The net profit attributable to shareholders was 12,357.58 million yuan, reflecting a year-on-year increase of 7.65% [2] Marketing Strategy - The company has tailored product planning and academic promotion strategies based on market research, enhancing brand building [2] - Training and improvement of sales personnel's capabilities have increased overall sales team efficiency [2] - The company is optimizing sales channels to consolidate existing markets while actively exploring potential markets [2] Research and Development - Key R&D projects are progressing, with improvements in organizational structure and innovation environment [2] - The company is focusing on enhancing R&D efficiency [2] Product Performance - Sales of the product "Sutai Sheng" have increased by over 15% year-on-year [4] - The product is performing well in provinces such as Zhejiang, Guangdong, Beijing, Shanghai, and Shaanxi [4] - "Sutai Sheng" holds the largest market share among nerve injury repair drugs, despite competition [4] Competitive Landscape - The market for nerve injury repair drugs is experiencing rapid compound growth, with "Sutai Sheng" benefiting from its effectiveness and fewer side effects [4] - The product is recognized for its direct repair action on nerve damage, distinguishing it from other neuroprotective agents [4] Regulatory and Clinical Guidelines - "Shutai Qing" is included as a first-choice medication in clinical guidelines for constipation [5] - The product is deemed safe and effective for various demographics, including the elderly, pregnant women, and children [6] Future Considerations - The company is considering new stock incentive plans after completing the current stock incentive expense [7] - There is an ongoing search for promising products or companies for potential acquisition [7] Sales Model - The marketing model for "Sutai Sheng" primarily employs a self-operated plus招商 (investment attraction) approach [7] - "Shutai Qing" also utilizes a similar sales model, with significant contributions from self-operated sales [7]

舒泰神（北京）生物制药股份有限公司接待投资者调研纪要 投资管理有限公司、某个人投资者 舒泰神调研纪要 时间：2015 年 04 月 24 日 | --- | |------------------------------------------------------| | | | 光大证券、太平洋证券、东方证券、民生证券、国联证券、 | | 长城基金、天弘基金、中信产业基金、嘉实基金、摩根 | | 士丹利华鑫基金、富国基金、泰康资产、上海承周资产 | | 管理有限公司、北京嘉承金信投资有限公司、南山集团 | | 资本投资有限公司、天马资产管理有限公司、广州长金 | 接待人：马莉娜 一、董事会秘书马莉娜介绍 2015 年第一季度业绩情况： 2015 年第一季度，公司实现营业总收入 23299.18 万元，比去年 同期增长 7.76%；归属于上市公司股东的净利润为 5044.41 万元，比 去年同期增长 41.81%。 营销方面，不断强化市场工作，高度重视各省招投标、价格维 护工作；深入研究所处市场环境，针对不同区域市场制定产品策划 和学术推广策略，持续加强品牌建设；通过对销售人员能力与素质 的培训与提升，提高 ...

证券代码：300204 证券简称:舒泰神 舒泰神（北京）生物制药股份有限公司 投资者关系活动记录表 编号：2015-002 | --- | --- | --- | |--------------|--------------------------|--------------------------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | | 光大证券、太平洋证券、东方证券、民生证券、国联证 | | | | 券、长城基金、天弘基金、中信产业基金、嘉实基金、 | | | | 摩根士丹利华鑫基金、富国基金、泰康资产、上海承周 | | | | 资产管理有限公司、北京嘉承金信投资有限公司、南 | | | | 山集团资本投资有限公司、天马资产管理有限公司、 | | | | 广州长金投资管理有限公司、某个人投资者 | | 时间 | 2015 年 04 月 ...

证券代码：300204 证券简称:舒泰神 舒泰神（北京）生物制药股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |--------------|--------------------------|--------------------------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | | 信诚人寿、泰达宏利基金、瑞泰人寿、中银国际、合众 | | | | 资产、中融人寿、星石投资、南方基金、常州投资集 | | | | 团、中国人寿资产管理、上海森钵投资、江苏省建工集 | | | 团装饰工程有限公司 | | | 时间 | 2015 年 03 月 18 | 日 | | 地点 | 公司会议室 | | | 上市公司接待 | 马莉娜 | | | 人员姓名 | | | | 投资者关系活 | | 产品情况 ...

Group 1: Sales and Market Position - Su Tai Shen's Su Tai Sheng sales volume in 2014 was 4,577,919 bottles [3] - Su Tai Sheng holds the largest market share among four domestic varieties of mouse nerve growth factor [4] Group 2: Product Development and Differentiation - The human nerve growth factor developed by the company is an upgraded product of mouse nerve growth factor, utilizing recombinant gene technology [5] - The human nerve growth factor has advantages in homology compared to mouse nerve growth factor [5] Group 3: International Expansion and Strategy - The U.S. subsidiary has established its work direction, completed site leasing and renovation, and initiated personnel recruitment [5] - The Hong Kong subsidiary aims to leverage the favorable business environment for international investment and financing activities in the biopharmaceutical field [6] Group 4: Product Safety and Efficacy - Mouse nerve growth factor is currently the clearest product for direct repair of nerve damage, with fewer adverse reactions and high safety, stability, and effectiveness [6] - Su Tai Qing is safe and effective for use by elderly individuals, pregnant women, and children [6] Group 5: Research and Development Investment - R&D investment is closely related to the progress and stages of R&D projects, with the company emphasizing innovative research without compromising investment due to external factors [6]

Sales Performance - Su Tai Shen's main product, Su Tai Sheng, accounted for 90% of total sales, generating approximately 1.1 billion in revenue in 2015, leading the market with the highest share among four competitors [1] - Sales of Shu Tai Qing reached around 100 million, with a market potential of 700-800 million annually in bowel preparation, positioning it as a first-line treatment [1][2] - Shu Tai Qing's sales growth was between 10%-20%, down from previous years' growth rates of over 30% [2] Research and Development - The company focuses on research in nerve damage, with ongoing projects for second and third-generation Su Tai Sheng, and gene therapy targeting hepatitis B and HIV [2] - Clinical trial applications for these projects are expected to be submitted in the following year [2] - The company is also exploring new products, with Su Tai Sheng showing over 20% growth in the first quarter compared to previous years [3] Future Strategy - The company aims to innovate in drug development and has established subsidiaries in the US and Hong Kong for talent acquisition and investment purposes [2] - Plans to increase sales include raising unit prices and expanding market coverage, especially in response to price reductions in the bidding process [3][4] Financial Insights - In 2015, the profit growth rate was 8%, with a non-recurring profit growth rate of 10%, meeting the criteria for the first phase of the stock incentive plan [4] - The company is considering early-stage investments in projects and technologies in the US [4] Market Opportunities - The market for the new drug, Qushi Chloride Capsules, is expected to grow due to increasing public awareness and demand, particularly as it addresses a new market segment [5] - The safety profile of Qushi Chloride is favorable, as it does not cross the blood-brain barrier, enhancing patient compliance [5]

Group 1: Company Overview - Shuyatshen (Beijing) Biopharmaceutical Co., Ltd. is identified with the stock code 300204 [1] - The investor relations activity took place on November 22, 2016 [2] Group 2: Investor Relations Activities - The activity type was a specific object investigation, with participation from various investment firms including Tianfeng Securities and Dongxing Securities [2] - The main topics discussed included company operations, research and development status, investment overview, and product sales [2]

舒泰神（北京）生物制药股份有限公司接待投资者调研纪要 舒泰神调研纪要 时间：2017 年 5 月 19 日 来访单位: 东兴证券、中信建投证券、华安资产、湾流投资、相聚资 本管理有限公司、北京壹玖资产管理公司、中融国际信 托有限公司、建信基金、中冀投资、远策投资 接待人：马莉娜 一、董事会秘书马莉娜介绍 2017 年公司发展情况： 2017 年中，公司的经营没有特别大的变化。在这里我主要简单 介绍一下产品、研发及公司未来的发展战略。舒泰神主要是在研发、 生产、销售全部流程为一体的公司，这是公司主要定位。在这里我 主要说一下公司销售、研发、和未来一段时间发展情况。 销售方面，新版医保目录的出台和未来一两年的招投标政策， 会让公司的销售面临一些比较严峻的挑战。从新版医保目录（2017 版）出来以后，对于神经生长因子的安全性、有效性和质量可控性 方面是一种肯定，但医疗体制改革的大方向会给神经生长因子带来 一些需要克服的困难。在 4 个上市的鼠神经生长因子产品中，销售 格局可能会有一些的变化。舒泰清一直列在医保目录里面，公司新 上市的产品舒唯欣（曲司氯铵胶囊）现在已经进入了大约 10 家医院 来进行销售。招投标方面， ...

Group 1: Market Position and Competitive Advantage - The company holds a significant market share in the pharmaceutical industry, ranking 29th among 39 companies in the "People's Finance Innovation Drug Index" [2] - Key products, Sutai Sheng and Shuitai Qing, are positioned within the top three in the market [3] - The company has developed a comprehensive competitive advantage through years of operation in the research, production, and commercialization of innovative biopharmaceuticals [3] Group 2: Future Plans and Market Demand - The company is considering the growing market demand due to population aging and has plans to address diseases related to this demographic [3] - The 2021 revenue target is set at no less than 471.5 million yuan, with expectations to register at least three drug production licenses, including two innovative biopharmaceuticals [4] - The company aims to enhance its marketing strategies, including online and offline integration, to maintain sales performance and market share for its products [4] Group 3: Research and Development Focus - The company has established a robust R&D pipeline, focusing on innovative biopharmaceuticals, with multiple projects expected to enter the IND application stage in the coming years [5] - Current R&D efforts are concentrated on treatment for neurodegenerative diseases, infectious diseases, and autoimmune diseases [5] - The company is confident in its ability to continuously provide safe and effective therapeutic drugs through its structured R&D phases [4][5] Group 4: Acquisitions and Strategic Moves - The acquisition of 100% of Sichuan Kaikang, now renamed Sichuan Shuitai Shen Pharmaceutical Co., is aimed at enhancing the company's sales platform and operational capabilities [4] - The company is actively working to maximize the value of this platform to support its overall business development [4] Group 5: Regulatory and Market Challenges - The company anticipates that its key products, Sutai Sheng and Shuitai Qing, will not enter the national centralized procurement directory in the short term [4] - The company is closely monitoring the market for Shuitai Qing to create retail demand and mitigate the impacts of centralized procurement [4]

Group 1: Company Overview - Shuotai Shen (Beijing) Biopharmaceutical Co., Ltd. is listed under the stock code 300204 [1] - The investor relations activity took place on May 19, 2021, from 15:30 to 16:30 [2] Group 2: Investor Relations Activity - The activity was categorized as a specific object survey [2] - Participants included various financial institutions such as Guosheng Securities Research Institute, CITIC Asset Management, and others [2] Group 3: Meeting Details - The meeting was held on the Guosheng Securities conference call platform [2] - Key representatives from the company included Ms. Marina, the Secretary of the Board, and Mr. Wang Chao, the Deputy General Manager [2] Group 4: Main Content - The main content included an introduction to the company's basic situation [2] - There was an interactive Q&A session with investors [2]